Kodiak Sciences Management
Management criteria checks 3/4
Kodiak Sciences' CEO is Victor Perlroth, appointed in Jun 2009, has a tenure of 14.92 years. total yearly compensation is $2.73M, comprised of 26.4% salary and 73.6% bonuses, including company stock and options. directly owns 5.15% of the company’s shares, worth $8.65M. The average tenure of the management team and the board of directors is 4.3 years and 5.9 years respectively.
Key information
Victor Perlroth
Chief executive officer
US$2.7m
Total compensation
| CEO salary percentage | 26.4% |
| CEO tenure | 14.9yrs |
| CEO ownership | 5.1% |
| Management average tenure | 4.3yrs |
| Board average tenure | 5.9yrs |
Recent management updates
Recent updates
We Think Kodiak Sciences (NASDAQ:KOD) Needs To Drive Business Growth Carefully
Apr 17
We Think Kodiak Sciences (NASDAQ:KOD) Needs To Drive Business Growth Carefully
Dec 29We're Keeping An Eye On Kodiak Sciences' (NASDAQ:KOD) Cash Burn Rate
Sep 09Is Kodiak Sciences (NASDAQ:KOD) In A Good Position To Deliver On Growth Plans?
May 26We Think Kodiak Sciences (NASDAQ:KOD) Needs To Drive Business Growth Carefully
Jan 04Here's Why We're Watching Kodiak Sciences' (NASDAQ:KOD) Cash Burn Situation
Sep 25GreenWood Investors - Kodiak Sciences: The Busted Biotech World
Aug 25Kodiak Sciences FQ1 2022 Earnings Preview
Aug 07Is Kodiak Sciences (NASDAQ:KOD) In A Good Position To Invest In Growth?
May 18Kodiak Sciences: Potential For Comeback After Trial Setback
May 17Kodiak Sciences: KSI-301 Disappoints
Feb 25Highlighting Kodiak Sciences: A Great Buy Here Ahead Of Phase 3 Wet AMD Data For KSI-301 This Quarter
Feb 15We're Hopeful That Kodiak Sciences (NASDAQ:KOD) Will Use Its Cash Wisely
Jan 24Here's Why We're Not Too Worried About Kodiak Sciences' (NASDAQ:KOD) Cash Burn Situation
Oct 11Kodiak Sciences: Our Current Take On This Mid-Cap Biotech Company
Jul 19Kodiak Sciences EPS in-line
May 10Kodiak Sciences hits the capital raise button; shares dip after hours
Nov 16Kodiak Sciences EPS misses by $0.12
Nov 09CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | US$3m | US$721k | -US$260m |
| Sep 30 2023 | n/a | n/a | -US$271m |
| Jun 30 2023 | n/a | n/a | -US$298m |
| Mar 31 2023 | n/a | n/a | -US$309m |
| Dec 31 2022 | US$3m | US$691k | -US$334m |
| Sep 30 2022 | n/a | n/a | -US$357m |
| Jun 30 2022 | n/a | n/a | -US$347m |
| Mar 31 2022 | n/a | n/a | -US$312m |
| Dec 31 2021 | US$113m | US$655k | -US$267m |
| Sep 30 2021 | n/a | n/a | -US$220m |
| Jun 30 2021 | n/a | n/a | -US$189m |
| Mar 31 2021 | n/a | n/a | -US$159m |
| Dec 31 2020 | US$9m | US$591k | -US$133m |
| Sep 30 2020 | n/a | n/a | -US$102m |
| Jun 30 2020 | n/a | n/a | -US$78m |
| Mar 31 2020 | n/a | n/a | -US$64m |
| Dec 31 2019 | US$18m | US$526k | -US$47m |
| Sep 30 2019 | n/a | n/a | -US$46m |
| Jun 30 2019 | n/a | n/a | -US$44m |
| Mar 31 2019 | n/a | n/a | -US$41m |
| Dec 31 2018 | US$6m | US$428k | -US$41m |
| Sep 30 2018 | n/a | n/a | -US$38m |
| Jun 30 2018 | n/a | n/a | -US$32m |
| Mar 31 2018 | n/a | n/a | -US$31m |
| Dec 31 2017 | US$824k | US$388k | -US$28m |
Compensation vs Market: Victor's total compensation ($USD2.73M) is above average for companies of similar size in the US market ($USD1.64M).
Compensation vs Earnings: Victor's compensation has been consistent with company performance over the past year.
CEO
Victor Perlroth (49 yo)
14.9yrs
Tenure
US$2,725,068
Compensation
Dr. Victor Perlroth, M.D co-founded Kodiak Sciences Inc. in 2009 and serves as its co-founder, Chairman, President and Chief Executive Officer. Dr. Perlroth serves as Chief Executive officer since June 200...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 14.9yrs | US$2.73m | 5.15% $ 8.7m | |
| Executive VP | 9.9yrs | US$1.68m | 0.34% $ 571.6k | |
| Senior Vice President of Discovery Medicine | 6.6yrs | US$321.91k | no data | |
| Senior Vice President of Chemical Development & Manufacturing | 1.3yrs | no data | no data | |
| Senior Vice President of Quality Operations | 4.3yrs | no data | no data | |
| Senior Vice President of Clinical Research & Development | 1.3yrs | no data | no data | |
| VP & Corporate Controller | 1.3yrs | no data | no data |
4.3yrs
Average Tenure
51yo
Average Age
Experienced Management: KOD's management team is considered experienced (4.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 14.9yrs | US$2.73m | 5.15% $ 8.7m | |
| Lead Independent Director | 5.9yrs | US$248.40k | 0.019% $ 32.1k | |
| Independent Director | 8.7yrs | US$161.90k | 0% $ 0 | |
| Independent Director | 5.9yrs | US$211.90k | 0.0019% $ 3.2k | |
| Independent Director | 5.9yrs | US$216.90k | 0% $ 0 | |
| Independent Director | 4.1yrs | US$239.40k | 0.050% $ 83.3k | |
| Scientific Advisor | no data | no data | no data | |
| Scientific Advisor | no data | no data | no data | |
| Scientific Advisor | no data | no data | no data | |
| Scientific Advisor | no data | no data | no data | |
| Scientific Advisor | no data | no data | no data | |
| Scientific Advisor | no data | no data | no data |
5.9yrs
Average Tenure
59yo
Average Age
Experienced Board: KOD's board of directors are considered experienced (5.9 years average tenure).